Praxis Precision Medicines

Biotech & Life Sciences · Cambridge, United States · Founded 2015 · IPO 2020

Developing therapies for central nervous system disorders based on genetic insights into neuronal imbalance MoreLess

Praxis Precision Medicines is a clinical stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, particularly those characterized by neuronal imbalance. The company leverages insights from genetic epilepsies to create innovative treatments aimed at addressing unmet medical needs. Praxis operates in the biopharmaceutical market, primarily serving patients with CNS disorders and their caregivers. The business model revolves around patient-guided development strategies, ensuring that the therapies developed are aligned with what patients actually need. Revenue is generated through the development and potential commercialization of these therapies, as well as through partnerships and collaborations with other entities in the healthcare sector.

Keywords: CNS disorders, genetic epilepsies, biopharmaceutical, therapies, neuronal imbalance, patient-guided, clinical stage, innovation, healthcare, partnerships.

Valuation $7.80B

Revenue $2.3M

Total funding $100–500M

Power Law Unicorn$1–10B valuation tier

Talent graph

Praxis Precision Medicines's talent

Book a demo to see the people

Team profiled 11 named & role-tagged

Founders /100 quality score

Key operators 5 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

14 investors on Praxis Precision Medicines's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 14 investors entered at this stage

Eventide Asset Management

Qatar Investment Authority

Point72 Ventures

Citadel

Blackstone

Adage Capital

Novo Holdings

Cormorant Asset Management

Vida Ventures

Irving Investors

OCV Partners

Avoro Capital Advisors

Verition Fund Management

Affinity Asset Advisors

Global footprint

Where Praxis Precision Medicines has talent and traffic

Workforce by country

5 countries with
team presence

🇺🇸 United States97%

🇦🇺 Australia1.2%

🇧🇷 Brazil0.6%

🇮🇳 India0.6%

🇨🇴 Colombia0.6%

5 countries shown

Web traffic by country

11K monthly visits
across markets

🇺🇸 United States71.8%

🇨🇦 Canada16.4%

🇮🇳 India9.1%

🇧🇷 Brazil3.6%

🇮🇹 Italy0.9%

Top 5 markets shown

Patent intelligence

$36M patent portfolio · 49 active families

Estimated portfolio value

$36M

0.46% of market cap · 5.3× smaller than top peer Moderna Therapeutics ($189M)

49 active patent families

Where Praxis Precision Medicines innovates BiochemistryCalcium channelDepressantDiseaseDravet syndrome

Where Praxis Precision Medicines concentrates vs peers

Each axis is a top-10 topic across Praxis Precision Medicines and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Praxis Precision Medicines

An AI-synthesized read of the highest-engagement posts about Praxis Precision Medicines on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Praxis Precision Medicines on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles